These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12431207)

  • 1. Interobserver variation in interpretation of serial liver biopsies from patients with chronic hepatitis C.
    Grønbaek K; Christensen PB; Hamilton-Dutoit S; Federspiel BH; Hage E; Jensen OJ; Vyberg M
    J Viral Hepat; 2002 Nov; 9(6):443-9. PubMed ID: 12431207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection.
    Westin J; Lagging LM; Wejstål R; Norkrans G; Dhillon AP
    Liver; 1999 Jun; 19(3):183-7. PubMed ID: 10395036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computer morphometry for quantitative measurement of liver fibrosis: comparison with Knodell's score, colorimetry and conventional description reports.
    Lin XZ; Horng MH; Sun YN; Shiesh SC; Chow NH; Guo XZ
    J Gastroenterol Hepatol; 1998 Jan; 13(1):75-80. PubMed ID: 9737576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological scoring of fibrosis and activity in HIV-chronic hepatitis B related liver disease: performance of the METAVIR score assessed on virtual slides.
    Wendum D; Lacombe K; Chevallier M; Callard P; Valet F; Miailhes P; Bonnard P; Molina JM; Lascoux-Combe C; Fléjou JF; Girard PM
    J Clin Pathol; 2009 Apr; 62(4):361-3. PubMed ID: 19126564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term changes in liver histology following treatment of chronic hepatitis C virus.
    Shiffman ML; Sterling RK; Contos M; Hubbard S; Long A; Luketic VA; Stravitz RT; Fuchs M; Sanyal AJ
    Ann Hepatol; 2014; 13(4):340-9. PubMed ID: 24927604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection.
    Tsubota A; Kumada H; Chayama K; Arase Y; Saitoh S; Koida I; Suzuki Y; Kobayashi M; Murashima N; Ikeda K
    J Hepatol; 1997 Jul; 27(1):49-55. PubMed ID: 9252073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C.
    Tanaka H; El-Karef A; Kaito M; Kinoshita N; Fujita N; Horiike S; Watanabe S; Yoshida T; Adachi Y
    Liver Int; 2006 Apr; 26(3):311-8. PubMed ID: 16584393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C.
    Schiano TD; Azeem S; Bodian CA; Bodenheimer HC; Merati S; Thung SN; Hytiroglou P
    Clin Gastroenterol Hepatol; 2005 Sep; 3(9):930-5. PubMed ID: 16234033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group.
    Hepatology; 1994 Jul; 20(1):15-20. PubMed ID: 8020885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic histology of patients with HIV infection and chronic hepatitis C treated with interferon.
    Boldorini R; Viganò P; Monga G; Nebuloni M; Cargnel A; Gubertini G; Migliaretti G; Costanzi G
    J Clin Pathol; 1997 Sep; 50(9):735-40. PubMed ID: 9389973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment.
    Shima T; Tada H; Morimoto M; Nakagawa Y; Obata H; Sasaki T; Park H; Nakajo S; Nakashima T; Okanoue T; Kashima K
    J Gastroenterol Hepatol; 2000 Mar; 15(3):294-9. PubMed ID: 10764031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A prospective study on histological and serological changes after interferon alpha-2b treatment in patients with chronic hepatitis B infection].
    Lang Z; Zhao C; Xu D
    Zhonghua Gan Zang Bing Za Zhi; 2001 Jun; 9(3):145-7. PubMed ID: 11517899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy.
    Wang X; Gao F; Yuan G; Shi K; Huang Y; Chen Y; Qiu R; Sun L; Liu J; Hu C; Zhou Y
    J Viral Hepat; 2016 Dec; 23(12):971-976. PubMed ID: 27453300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
    Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
    Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation.
    Manabe N; Chevallier M; Chossegros P; Causse X; Guerret S; Trépo C; Grimaud JA
    Hepatology; 1993 Dec; 18(6):1344-9. PubMed ID: 8244259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inter-observes agreement of Ishak and Metavir scores in histological evaluation of chronic viral hepatitis B and C].
    Rammeh S; Khadra HB; Znaidi NS; Romdhane NA; Najjar T; Bouzaidi S; Zermani R
    Ann Biol Clin (Paris); 2014; 72(1):57-60. PubMed ID: 24492098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological change after interferon therapy in chronic hepatitis C in view of iron deposition in the liver.
    Kakizaki S; Takagi H; Ichikawa T; Abe T; Yamada T; Suzuki K; Kojima A; Takayama H; Takezawa J; Nagamine T; Mori M
    Biol Trace Elem Res; 2000 Feb; 73(2):151-62. PubMed ID: 11049207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic expression of viral antigens, hepatocytic proliferative activity and histologic changes in liver biopsies of children with chronic hepatitis B after interferon-alpha therapy.
    Ozer E; Ozer E; Helvaci M; Yaprak I
    Liver; 1999 Oct; 19(5):369-74. PubMed ID: 10533793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serologic response against hepatitis C virus as a predictive factor to the treatment with interferon].
    Garrido A; Lepe JA; Guerrero FJ; Palomo S
    Enferm Infecc Microbiol Clin; 2000 Dec; 18(10):512-5. PubMed ID: 11198002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between quantitative electroencephalographic alterations and the severity of hepatitis C based on liver biopsy in interferon-alpha treated patients.
    Kamei S; Morita A; Tanaka N; Matsuura M; Moriyama M; Kojima T; Arakawa Y; Matsukawa Y; Mizutani T; Sakai T; Oga K; Ohkubo H; Matsumura H; Hirayanagi K
    Intern Med; 2009; 48(12):975-80. PubMed ID: 19525583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.